Literature DB >> 27995085

Transarterial Therapies for Hepatocellular Carcinoma.

Ezio Lanza1, Matteo Donadon2, Dario Poretti1, Vittorio Pedicini1, Marco Tramarin1, Massimo Roncalli3, Hyungjin Rhee4, Young Nyun Park5, Guido Torzilli2.   

Abstract

BACKGROUND: The treatment of hepatocellular carcinoma (HCC) is still a major health issue because of its increasing incidence and because of the complexity of its management. Transarterial embolization (TAE) and transarterial chemoembolization (TACE) are two widely used locoregional therapies in the treatment of HCC, especially for unresectable intermediate and advanced HCCs.
SUMMARY: The modern use of TAE and TACE opens new scenarios for the treatment of unresectable HCC and has yielded interesting results. The present work describes the role of transarterial therapies for HCC and focuses on the different Western and Eastern approaches to the study of response predictors. KEY MESSAGES: Recent refinements in interventional radiology techniques and in HCC patient selection have facilitated better local control of the disease. The molecular profiling of HCC to predict the response to TACE and TAE will greatly help clinicians identify the optimum therapy.

Entities:  

Keywords:  Predictors of response after TAE and TACE for HCC; TAE and TACE for HCC

Year:  2016        PMID: 27995085      PMCID: PMC5159740          DOI: 10.1159/000449347

Source DB:  PubMed          Journal:  Liver Cancer        ISSN: 1664-5553            Impact factor:   11.740


  35 in total

1.  Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation.

Authors:  Bruno Sangro; Livio Carpanese; Roberto Cianni; Rita Golfieri; Daniele Gasparini; Samer Ezziddin; Philipp M Paprottka; Francesco Fiore; Mark Van Buskirk; Jose Ignacio Bilbao; Giuseppe Maria Ettorre; Rita Salvatori; Emanuela Giampalma; Onelio Geatti; Kai Wilhelm; Ralf Thorsten Hoffmann; Francesco Izzo; Mercedes Iñarrairaegui; Carlo Ludovico Maini; Carlo Urigo; Alberta Cappelli; Alessandro Vit; Hojjat Ahmadzadehfar; Tobias Franz Jakobs; Secondo Lastoria
Journal:  Hepatology       Date:  2011-06-30       Impact factor: 17.425

2.  Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study.

Authors:  Ronnie Tung-Ping Poon; Irene Oi-Lin Ng; Cecilia Lau; Wun-Ching Yu; Zhen-Fan Yang; Sheung-Tat Fan; John Wong
Journal:  J Clin Oncol       Date:  2002-04-01       Impact factor: 44.544

3.  Does the hepatitis B antigen HBx promote the appearance of liver cancer stem cells?

Authors:  Alla Arzumanyan; Tiffany Friedman; Irene O L Ng; Marcia M Clayton; Zhaorui Lian; Mark A Feitelson
Journal:  Cancer Res       Date:  2011-04-04       Impact factor: 12.701

4.  The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype.

Authors:  John M Heddleston; Zhizhong Li; Roger E McLendon; Anita B Hjelmeland; Jeremy N Rich
Journal:  Cell Cycle       Date:  2009-10-03       Impact factor: 4.534

5.  Bland embolization in patients with unresectable hepatocellular carcinoma using precise, tightly size-calibrated, anti-inflammatory microparticles: first clinical experience and one-year follow-up.

Authors:  Guido Bonomo; Vittorio Pedicini; Lorenzo Monfardini; Paolo Della Vigna; Dario Poretti; Gianluigi Orgera; Franco Orsi
Journal:  Cardiovasc Intervent Radiol       Date:  2009-12-03       Impact factor: 2.740

6.  Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma.

Authors:  Katerina Malagari; Mary Pomoni; Alexis Kelekis; Anastasia Pomoni; Spyros Dourakis; Themis Spyridopoulos; Hippokratis Moschouris; Emmanouil Emmanouil; Spyros Rizos; Dimitrios Kelekis
Journal:  Cardiovasc Intervent Radiol       Date:  2009-11-24       Impact factor: 2.740

Review 7.  Cancer stem cells, the epithelial to mesenchymal transition (EMT) and radioresistance: potential role of hypoxia.

Authors:  Delphine Tamara Marie-Egyptienne; Ines Lohse; Richard Peter Hill
Journal:  Cancer Lett       Date:  2012-11-28       Impact factor: 8.679

8.  Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.

Authors:  Riccardo Lencioni; Josep M Llovet; Guohong Han; Won Young Tak; Jiamei Yang; Alfredo Guglielmi; Seung Woon Paik; Maria Reig; Do Young Kim; Gar-Yang Chau; Angelo Luca; Luis Ruiz Del Arbol; Marie-Aude Leberre; Woody Niu; Kate Nicholson; Gerold Meinhardt; Jordi Bruix
Journal:  J Hepatol       Date:  2016-01-22       Impact factor: 25.083

9.  Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study.

Authors:  Brian I Carr; Venkateswarlu Kondragunta; Shama C Buch; Robert A Branch
Journal:  Cancer       Date:  2010-03-01       Impact factor: 6.860

Review 10.  Hepatic radioembolization as a bridge to liver surgery.

Authors:  Arthur J A T Braat; Julia E Huijbregts; I Quintus Molenaar; Inne H M Borel Rinkes; Maurice A A J van den Bosch; Marnix G E H Lam
Journal:  Front Oncol       Date:  2014-07-30       Impact factor: 6.244

View more
  24 in total

Review 1.  The role of microRNA in the resistance to treatment of hepatocellular carcinoma.

Authors:  Muhammad Yogi Pratama; Devis Pascut; Muhammad Nasrum Massi; Claudio Tiribelli
Journal:  Ann Transl Med       Date:  2019-10

2.  A pure nanoICG-based homogeneous lipiodol formulation: toward precise surgical navigation of primary liver cancer after long-term transcatheter arterial embolization.

Authors:  Yang Zhang; Hongwei Cheng; Hu Chen; Peiyao Xu; En Ren; Yonghe Jiang; Dengfeng Li; Xing Gao; Yating Zheng; Pan He; Huirong Lin; Biaoqi Chen; Gan Lin; Aizheng Chen; Chengchao Chu; Jingsong Mao; Gang Liu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-12-23       Impact factor: 10.057

3.  Prediction of post-TACE necrosis of hepatocellular carcinoma usingvolumetric enhancement on MRI and volumetric oil deposition on CT, with pathological correlation.

Authors:  Farnaz Najmi Varzaneh; Ankur Pandey; Mounes Aliyari Ghasabeh; Nannan Shao; Pegah Khoshpouri; Pallavi Pandey; Manijeh Zarghampour; Daniel Fouladi; Robert Liddell; Robert Albert Anders; Ihab R Kamel
Journal:  Eur Radiol       Date:  2018-01-30       Impact factor: 5.315

4.  A machine learning model to predict hepatocellular carcinoma response to transcatheter arterial chemoembolization.

Authors:  Ali Morshid; Khaled M Elsayes; Ahmed M Khalaf; Mohab M Elmohr; Justin Yu; Ahmed O Kaseb; Manal Hassan; Armeen Mahvash; Zhihui Wang; John D Hazle; David Fuentes
Journal:  Radiol Artif Intell       Date:  2019-09-25

Review 5.  Patient Selection for Transarterial Chemoembolization in Hepatocellular Carcinoma: Importance of Benefit/Risk Assessment.

Authors:  Fabio Piscaglia; Sadahisa Ogasawara
Journal:  Liver Cancer       Date:  2018-01-12       Impact factor: 11.740

6.  High expression of the TEFM gene predicts poor prognosis in hepatocellular carcinoma.

Authors:  Zai-Yi Fei; Wei-Si Wang; Su-Fen Li; Jia-Ji Zi; Li Yang; Ting Liu; Song Ao; Qian-Qian Liu; Qing-Hua Cui; Min Yu; Wei Xiong
Journal:  J Gastrointest Oncol       Date:  2020-12

7.  Strategies for prediction and mitigation of radiation-induced liver toxicity.

Authors:  Diego A S Toesca; Bulat Ibragimov; Amanda J Koong; Lei Xing; Albert C Koong; Daniel T Chang
Journal:  J Radiat Res       Date:  2018-03-01       Impact factor: 2.724

Review 8.  Imaging Evaluation Following 90Y Radioembolization of Liver Tumors: What Radiologists Should Know.

Authors:  Ijin Joo; Hyo-Cheol Kim; Gyoung Min Kim; Jin Chul Paeng
Journal:  Korean J Radiol       Date:  2018-02-22       Impact factor: 3.500

9.  Microvascular invasion may be the determining factor in selecting TACE as the initial treatment in patients with hepatocellular carcinoma.

Authors:  Joonho Jeong; Jung Gu Park; Kwang Ill Seo; Ji Hyun Ahn; Jae Chun Park; Byung Cheol Yun; Sang Uk Lee; Jin Wook Lee; Jong Hyouk Yun
Journal:  Medicine (Baltimore)       Date:  2021-07-09       Impact factor: 1.889

10.  Hyaluronic acid-based nano-sized drug carrier-containing Gellan gum microspheres as potential multifunctional embolic agent.

Authors:  Ming Fang Hsu; Yen Sheng Tyan; Yu Chen Chien; Ming Wei Lee
Journal:  Sci Rep       Date:  2018-01-15       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.